Skip to content

Effect of Bacillus Calmette-Guérin vaccination on the immunogenicity of the mRNA BNT162b2 COVID-19 vaccine in health care workers

Effect of Bacillus Calmette-Guérin vaccination on the immunogenicity of the mRNA BNT162b2 COVID-19 vaccine in health care workers - COMBI study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON50881
Enrollment
20
Registered
2021-01-21
Start date
2021-04-12
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corona COVID-19

Interventions

One group has been vaccinated with BCG in the past 12 months and will be vaccinated with the COVID-19 vaccine from Pfizer/BioNTech. The other group has never been vaccinated with BCG and will be vac

Sponsors

Interne Geneeskunde
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age equal to or above 18 years; - Written informed consent provided by the participant; - Receiving BioNTech/Pfizer COVID-19 vaccine per routine care; - Having received BCG-vaccination in the past 12 months OR never having received BCG-vaccination.

Exclusion criteria

Exclusion criteria: - Legally incapacitated or unwilling to provide informed consent; - History of COVID-19 infection, confirmed by a microbiological test.

Design outcomes

Primary

MeasureTime frame
Serological titer of IgG to the SARS-CoV-2 spike protein at 6 and 12 months after the Pfizer/BioNTech BNT162B2 vaccination.

Secondary

MeasureTime frame
- Geometric mean concentrations (GMCs) of RBD- and S-specific IgG, IgA and IgM in serum at day 35 after the first dose of the Pfizer/BioNTech BNT162B2 vaccination; - IgG, IgA and IgM concentrations against SARS-CoV-2 antigens in nasal mucosal lining fluid at the various sampling time points. - Local reactions at injection site or systemic reactions after COVID-19 vaccination. - T-cell responses and monocyte cytokine response to ex vivo stimulation at the various time points.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)